Rubius Therapeutics developed our proprietary RED PLATFORM® to generate red blood cells and genetically engineer them into a new class of cellular medicines, called Red Cell Therapeutics™ (RCTs). Our RED PLATFORM harnesses both the unique properties of red blood cells and the creative potential of genetic engineering to deliver on the promise of cellular therapy and transform how diseases are treated.
Red Cell Therapeutics are engineered to express biotherapeutic proteins within or on their cell surface to create highly selective, potent and allogeneic cellular medicines aimed at treating a range of diseases. They can potentially be used to replace missing enzymes for patients living with certain rare enzyme deficiencies, kill tumors in cancer and regulate the immune system for the treatment of autoimmune diseases.
Rubius Therapeutics is currently enrolling patients in a Phase 1 clinical trial to evaluate RTX-134 for the treatment of phenylketonuria. An Investigational New Drug (IND) application is under review with the U.S. FDA for our lead cancer program, RTX-240, for the treatment of solid tumors. By year-end, Rubius we expect to file an IND for RTX-321 for the treatment of HPV-positive cancers.